Company news

Pliant Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 5, 2024

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

March 26, 2024

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

March 11, 2024

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

February 26, 2024

Pliant Therapeutics to Participate in Upcoming Investor Conferences

February 25, 2024

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

February 3, 2024

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

November 12, 2023

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 8, 2023

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

November 5, 2023

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

October 30, 2023

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

October 18, 2023

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

October 15, 2023

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

September 25, 2023

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

September 24, 2023

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

September 14, 2023

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

September 10, 2023

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

August 27, 2023

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 8, 2023

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

August 8, 2023

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

June 22, 2023

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 8, 2023

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

April 29, 2023

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

April 11, 2023

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

March 26, 2023

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

March 12, 2023

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

March 8, 2023

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

March 7, 2023

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

February 1, 2023

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

January 26, 2023

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

January 24, 2023

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

January 23, 2023

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

January 22, 2023

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

January 21, 2023

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

December 14, 2022

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 7, 2022

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

October 4, 2022

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

September 14, 2022

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

August 31, 2022

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 7, 2022

Pliant Therapeutics to Participate in BTIG Biotechnology Conference

August 1, 2022

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

July 20, 2022

Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering

July 11, 2022

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

July 9, 2022

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

June 23, 2022

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

June 21, 2022

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

June 15, 2022

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

June 14, 2022

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

May 17, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 9 decks. Every deck is listed under its year.